There are countless reasons why I will be attending the ISPE 2017 Europe Annual Conference, but for the sake of time, I’ve narrowed it down to my top three.
April 4th – Accelerated Development – Afternoon Session The industry and regulatory speakers will touch on trends and potential solutions, including faster selection of drug candidates and clinical trials with Advanced Therapy Medicinal Products (ATMP).
April 5th – GDP & GMP Annex 15 Risk Management – Morning Session You will get brand new regulatory updates and hear various case studies. One focus will be on Direct-to-Patient supplies. Share and learn more in a planned risk based distribution workshop.
April 5th – Patient Centricity & Innovative Supply Chain Approaches – Afternoon Session Listen to patient representatives, clinical supply chain and technology experts and discuss how value can be created for patients in clinical trials.
I’m looking forward to this unique opportunity to enhance my technical knowledge, exchange ideas with my peers, and gain insight from industry experts. I’m looking forward to seeing you at the 2017 ISPE Europe Annual Conference! By: Jens Mattuschka World Courier, an AmerisourceBergen company RVP | Nordics, Central and Eastern Europe
In the pharmaceutical industry, which is highly regulated, aseptic processing is a critical component that ensures the sterility of products. Regulators have a set of comprehensive requirements that minimize the risk of contamination. Regulators set the requirements; however, the industry has an obligation to the patients who rely on and expect a drug that is safe and free of contamination....
Like any investment in digital manufacturing systems, demonstrating business payback before and after investment is critical to getting MES projects approved and verifying profitability after investment. Whether it is introducing MES, expanding it to additional sites, switching software, upgrading existing software, or developing electronic production records (EPR) for new drug products,...
Sustainability is emerging as a pivotal force influencing the pharmaceutical industry’s dynamics and steering companies towards transformative change. The focus of this analysis is to delve into the sustainability key performance indicators (KPIs) of prominent pharmaceutical players, namely Pfizer, Sanofi, Glaxo Smith Kline (GSK), Becton Dickinson, Johnson & Johnson, Abbott, Eli Lilly, and...